Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
Sponsor: Revolution Medicines, Inc.
A observational or N/A phase clinical study on Colorectal Cancer and Non-Small Cell Lung Cancer (NSCLC), this trial is actively recruiting participants. The trial is conducted by Revolution Medicines, Inc. and has accumulated 13 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)This is an open-label, multicenter, Phase 1b/2 study evaluating elironrasib and daraxonrasib, administered as monotherapy and in combination, in patients with advanced KRAS G12C-mutated solid tumors to determine the maximum tolerated dose (MTD), identify the recommended Phase 2 dose and schedule (RP2DS), and preliminarily assess antitumor activity.
The study includes a Phase 1b dose escalation and expansion of combination therapy, followed by a Phase 2 evaluation of the selected RP2DS as monotherapy and combination therapy to further assess safety and antitumor activity.
This is an open-label, multicenter, Phase 1b/2 study evaluating elironrasib and daraxonrasib, administered as monotherapy and in combination, in patients with advanced KRAS G12C-mutated solid tumors to determine the maximum tolerated dose (MTD), identify the recommended Phase 2 dose and schedule (RP2DS), and preliminarily assess antitumor activity.
The study includes a Phase 1b dose escalation and expansion of combination therapy, followed by a Phase 2 evaluation of the selected RP2DS as monotherapy and combination therapy to further assess safety and antitumor activity.
Status Flow
Change History
13 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1 → PHASE1/PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Apr 2025 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Contact Information
- Revolution Medicines, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Ancona, Italy , Angers, France , Aurora, United States , Aviano, Italy , Barcelona, Spain , Barcelona, Spain , Bordeaux, France , Boston, United States , Bron, France and 43 more locations